PMID- 34489208
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20231108
IS  - 2405-8025 (Electronic)
IS  - 2405-8033 (Print)
IS  - 2405-8025 (Linking)
VI  - 7
IP  - 12
DP  - 2021 Dec
TI  - HLA class I antigen processing machinery defects in antitumor immunity and 
      immunotherapy.
PG  - 1089-1101
LID - S2405-8033(21)00159-X [pii]
LID - 10.1016/j.trecan.2021.07.006 [doi]
AB  - Human leukocyte antigen (HLA) class I antigen-processing machinery (APM) plays a 
      crucial role in the synthesis and expression of HLA class I tumor antigen-derived 
      peptide complexes; the latter mediate the recognition and elimination of 
      malignant cells by cognate T cells. Defects in HLA class I APM component 
      expression and/or function are frequently found in cancer cells, providing them 
      with an immune escape mechanism that has relevance in the clinical course of the 
      disease and in the response to T-cell-based immunotherapy. The majority of HLA 
      class I APM defects (>75%) are caused by epigenetic mechanisms or dysregulated 
      signaling and therefore can be corrected by strategies that counteract the 
      underlying mechanisms. Their application in oncology is likely to improve 
      responses to T-cell-based immunotherapies, including checkpoint inhibition.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Maggs, Luke
AU  - Maggs L
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, USA. Electronic address: lmaggs1@mgh.harvard.edu.
FAU - Sadagopan, Ananthan
AU  - Sadagopan A
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Moghaddam, Ali Sanjari
AU  - Moghaddam AS
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Ferrone, Soldano
AU  - Ferrone S
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, USA. Electronic address: sferrone@mgh.harvard.edu.
LA  - eng
GR  - P01 CA089480/CA/NCI NIH HHS/United States
GR  - R03 CA219603/CA/NCI NIH HHS/United States
GR  - R01 DE028172/DE/NIDCR NIH HHS/United States
GR  - R01 CA230275/CA/NCI NIH HHS/United States
GR  - R03 CA253319/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20210903
PL  - United States
TA  - Trends Cancer
JT  - Trends in cancer
JID - 101665956
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - *Antigen Presentation
MH  - HLA Antigens
MH  - Histocompatibility Antigens Class I
MH  - Humans
MH  - *Immunotherapy
MH  - T-Lymphocytes
PMC - PMC8651070
MID - NIHMS1738191
OTO - NOTNLM
OT  - HLA class I
OT  - T cell recognition
OT  - antigen-processing machinery
OT  - epigenetics
OT  - immune escape
OT  - immunosurveillance
COIS- Declaration of interests The authors have no interests to declare.
EDAT- 2021/09/08 06:00
MHDA- 2022/04/06 06:00
PMCR- 2022/12/01
CRDT- 2021/09/07 06:16
PHST- 2021/03/03 00:00 [received]
PHST- 2021/07/28 00:00 [revised]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2021/09/07 06:16 [entrez]
PHST- 2022/12/01 00:00 [pmc-release]
AID - S2405-8033(21)00159-X [pii]
AID - 10.1016/j.trecan.2021.07.006 [doi]
PST - ppublish
SO  - Trends Cancer. 2021 Dec;7(12):1089-1101. doi: 10.1016/j.trecan.2021.07.006. Epub 
      2021 Sep 3.